Medis_logo + tagline 2020 transparent png
QFR® allows for identification of lesion risk over a prolonged period of time

QFR® allows for identification of lesion risk over a prolonged period of time

QFR® identified additional lesions at risk for future nontarget vessel–related events in STEMI through 5 years of follow up.

Dr Sarah Bär et al from Univ of Bern, Switzerland carried out a retrospective QFR analysis of untreated nontarget vessels from the COMFORTABLE AMI Trial in 946 vessels from 617 patients. Conclusion: in STEMI-patients undergoing angiography-guided complete revascularization of all nonculprit lesions with ≥70% stenosis by visual estimate, QFR identified additional lesions at risk for future nontarget vessel–related events through 5 years of follow-up.

Read the article here

Learn more on the benefits of QFR®